CCR5 and HIV infectious disease: Maraviroc, a C–C chemokine receptor type 5 (CCR5) antagonist that blocks CCR5-mediated inflammation that is approved for the treatment of CCR5-tropic HIV infection (40), has also been used as a treatment approach for PML associated IRIS (14, 41).